Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
Subscribe To Our Newsletter & Stay Updated
